Home > Press > CombiMatrix Announces $1.5 Million Redemption of Auction Rate Securities
CombiMatrix Corporation (Nasdaq:CBMX) announced today that all of its $1.5 million in auction rate securities were recently liquidated at par value. Earlier in 2008, CombiMatrix had reported that these securities had become illiquid due to the global financial credit crisis.
CombiMatrix Announces $1.5 Million Redemption of Auction Rate Securities
MUKILTEO, WA | Posted on January 10th, 2009
"We are pleased to have this $1.5 million of cash available for execution and expansion of our diagnostics business. We also look forward to collecting the $36 million federal court judgment from National Union in the future," stated Dr. Amit Kumar, President and CEO of CombiMatrix.
About CombiMatrix Corporation
We are a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. We have also developed the capabilities of producing arrays that utilize bacterial artificial chromosomes on our arrays, also enabling genetic analysis. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. (CMDX), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.
Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985 CBMX (2269). Additional information about our laboratory, CMDX, is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory, and competitive developments, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Investor Relations Contact:
Amit Kumar, Ph.D., President & CEO
Fax: (425) 493-2010
Copyright © GlobeNewswire, Inc.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014
Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014
From Narrow to Broad July 30th, 2014
FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014
Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
Nanometrics Announces Upcoming Investor Events July 22nd, 2014
Harris & Harris Group Invests in UberSeq, Inc. July 16th, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014
FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014
University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014
Nature inspires a greener way to make colorful plastics July 30th, 2014
Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014
FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014